Avalon Ventures XI, L.P. - Sep 6, 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
10%+ Owner
Signature
Avalon Ventures XI, L.P., By: Avalon Ventures XI GP, LLC, its general partner, By /s/ Jay B. Lichter, Authorized Signatory
Stock symbol
JANX
Transactions as of
Sep 6, 2024
Transactions value $
-$10,134,526
Form type
4
Date filed
9/10/2024, 05:02 PM
Previous filing
Jun 5, 2024
Next filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Sale -$4.55M -108K -3.31% $42.00 3.16M Sep 6, 2024 Direct F1
transaction JANX Common Stock Sale -$882K -21K -3.31% $42.00 613K Sep 6, 2024 By Avalon BioVentures I, LP F2
transaction JANX Common Stock Sale -$4.65M -111K -3.31% $42.00 3.23M Sep 6, 2024 By Avalon BioVentures SPV I, L.P. F3
transaction JANX Common Stock Options Exercise $16.9K +994 +14.03% $17.00 8.08K Sep 9, 2024 Direct F4
transaction JANX Common Stock Options Exercise $4.44K +414 +5.13% $10.73 8.49K Sep 9, 2024 Direct F4
transaction JANX Common Stock Options Exercise $5.47K +414 +4.88% $13.22 8.91K Sep 9, 2024 Direct F4
transaction JANX Common Stock Options Exercise $11K +277 +3.11% $39.80 9.18K Sep 9, 2024 Direct F4
transaction JANX Common Stock Sale -$92.4K -2.18K -23.76% $42.33 7K Sep 9, 2024 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Options Exercise $0 -994 -3.31% $0.00 29K Sep 9, 2024 Common Stock 994 $17.00 Direct F4, F6
transaction JANX Stock Option (right to buy) Options Exercise $0 -414 -3.31% $0.00 12.1K Sep 9, 2024 Common Stock 414 $10.73 Direct F4, F6
transaction JANX Stock Option (right to buy) Options Exercise $0 -414 -3.31% $0.00 12.1K Sep 9, 2024 Common Stock 414 $13.22 Direct F4, F6
transaction JANX Stock Option (right to buy) Options Exercise $0 -277 -3.32% $0.00 8.07K Sep 9, 2024 Common Stock 277 $39.80 Direct F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F2 The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F3 The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F4 The securities are directly held by Mr. Lichter.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.33 to $42.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Immediately exercisable.